Inter and intra-tumor genetic heterogeneity for BRAF status was also suggested by microdissection technique followed by molecular analysis supporting the need for testing multiple sites in a single patient or to use blood-based mutation-detection method [34]. This evidence concerns the gene BRAF and neoplasm.